The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB

Inhibitors of NF-κB signaling: 785 and counting

“…These molecules inhibit the chymotrypsinlike activity of the proteasome complex (one of the five protease activities of the eukaryotic proteasome), but with distinct efficiencies. ALLnL, also called calpain inhibitor I or MG101, is a cysteine protease inhibitor, but is a less potent inhibitor of the proteasome than MG132 and MG115 (Palombella et al, 1994;Jobin et al, 1998a;Grisham et al, 1999).…”

Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1

“…Transcriptional response to stress signals like proteasome inhibitor treatment is a complex process (Palombella et al, 1994;Ichihara and Tanaka, 1995;Firestein and Feuerstein, 1998;Hofmann et al, 1996;Bonvini et al, 1998) with the response of many genes being dependent on crosstalk between signal transduction pathways and cell type speci®c factors.…”

Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes

“…NFKB1 and NFKB2 also encode two shorter proteins, p50 NF-kB-1 and p52 NF-kB-2, which are composed of the Nterminal RHD sequences without the C-terminal ankyrin domains, and which do not contain discrete transcriptional activation domains. p50 NF-kB-1 and p52 NF-kB-2 are formed as a result of proteolysis, likely by the ubiquitin-proteasome pathway (Palombella et al, 1994). This processing, leading to the removal of the tandem ankyrin repeats of the p105 NF-kB-1 and p100 NF-kB-2 precursor proteins, is dependent on glycine-rich sequences lying distal to the RHDs in these proteins (Lin and Ghosh, 1996).…”